Blanc A - Search Results

1

What lessons can be learned from γδ T cell-based cancer immunotherapy trials?

Fournié JJ, Sicard H, Poupot M, Bezombes C, Blanc A, Romagné F, Ysebaert L, Laurent G. Fournié JJ, et al. Among authors: blanc a. Cell Mol Immunol. 2013 Jan;10(1):35-41. doi: 10.1038/cmi.2012.39. Epub 2012 Dec 17. Cell Mol Immunol. 2013. PMID: 23241899 Free PMC article. Review.

2

Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy.

Ysebaert L, Gross E, Kühlein E, Blanc A, Corre J, Fournié JJ, Laurent G, Quillet-Mary A. Ysebaert L, et al. Among authors: blanc a. Leukemia. 2010 Jul;24(7):1310-6. doi: 10.1038/leu.2010.89. Epub 2010 May 13. Leukemia. 2010. PMID: 20463751

3

Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia.

Laprevotte E, Ysebaert L, Klein C, Valleron W, Blanc A, Gross E, Laurent G, Fournié JJ, Quillet-Mary A. Laprevotte E, et al. Among authors: blanc a. Leuk Res. 2013 Apr;37(4):440-6. doi: 10.1016/j.leukres.2012.11.015. Epub 2012 Dec 20. Leuk Res. 2013. PMID: 23259986

4

The serine-threonine kinase p90RSK is a new target of enzastaurin in follicular lymphoma cells.

Kheirallah S, Fruchon S, Ysebaert L, Blanc A, Capilla F, Marrot A, Alsaati T, Frenois FX, Benhadji KA, Fournié JJ, Laurent G, Bezombes C. Kheirallah S, et al. Among authors: blanc a. Br J Pharmacol. 2013 Dec;170(7):1374-83. doi: 10.1111/bph.12351. Br J Pharmacol. 2013. PMID: 23992368 Free PMC article.

5

Cell growth in aggregates determines gene expression, proliferation, survival, chemoresistance, and sensitivity to immune effectors in follicular lymphoma.

Gravelle P, Jean C, Familiades J, Decaup E, Blanc A, Bezombes-Cagnac C, Laurent C, Savina A, Fournié JJ, Laurent G. Gravelle P, et al. Among authors: blanc a. Am J Pathol. 2014 Jan;184(1):282-95. doi: 10.1016/j.ajpath.2013.09.018. Epub 2013 Nov 11. Am J Pathol. 2014. PMID: 24231431 Free article.

6

PKC zeta mTOR pathway: a new target for rituximab therapy in follicular lymphoma.

Leseux L, Laurent G, Laurent C, Rigo M, Blanc A, Olive D, Bezombes C. Leseux L, et al. Among authors: blanc a. Blood. 2008 Jan 1;111(1):285-91. doi: 10.1182/blood-2007-04-085092. Epub 2007 Sep 12. Blood. 2008. PMID: 17855629 Free article.

7

Epidermal growth factor receptor/beta-catenin/T-cell factor 4/matrix metalloproteinase 1: a new pathway for regulating keratinocyte invasiveness after UVA irradiation.

Jean C, Blanc A, Prade-Houdellier N, Ysebaert L, Hernandez-Pigeon H, Al Saati T, Haure MJ, Coluccia AM, Charveron M, Delabesse E, Laurent G. Jean C, et al. Among authors: blanc a. Cancer Res. 2009 Apr 15;69(8):3291-9. doi: 10.1158/0008-5472.CAN-08-1909. Epub 2009 Mar 31. Cancer Res. 2009. PMID: 19336574

8

Epidermal growth factor receptor pathway mitigates UVA-induced G2/M arrest in keratinocyte cells.

Jean C, Hernandez-Pigeon H, Blanc A, Charveron M, Laurent G. Jean C, et al. Among authors: blanc a. J Invest Dermatol. 2007 Oct;127(10):2418-24. doi: 10.1038/sj.jid.5700863. Epub 2007 May 10. J Invest Dermatol. 2007. PMID: 17495959 Free article.

9

Statistical behavior of joint least-square estimation in the phase diversity context.

Idier J, Mugnier L, Blanc A. Idier J, et al. Among authors: blanc a. IEEE Trans Image Process. 2005 Dec;14(12):2107-16. doi: 10.1109/tip.2005.859365. IEEE Trans Image Process. 2005. PMID: 16370463

10

Marginal estimation of aberrations and image restoration by use of phase diversity.

Blanc A, Mugnier LM, Idier J. Blanc A, et al. J Opt Soc Am A Opt Image Sci Vis. 2003 Jun;20(6):1035-45. doi: 10.1364/josaa.20.001035. J Opt Soc Am A Opt Image Sci Vis. 2003. PMID: 12801171

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

420 results

Search Page